Ecuadorean Laron syndrome study examines clues to lower cancer rates

The comparison is valuable because the normal-height relatives lived in the same villages, allowing researchers to examine whether a biological difference may help explain contrasting disease rates while reducing, not removing, some environmental differences. If researchers can identify which mechanisms are protective and reproduce them safely, the findings could inform future approaches to cancer prevention for people without the syndrome. That prospect remains distant: observed rates in a rare-condition cohort are not proof of cause and effect, and they do not justify changing cancer screening, diet, or treatment. The report also makes clear that individuals with Laron syndrome still need ordinary preventive care and medical attention.

Laron syndrome, also called growth hormone insensitivity, arises when mutations affecting the growth hormone receptor prevent the body from using its own growth hormone effectively. The BBC reports that the resulting low production of insulin-like growth factor 1 (IGF-1) is central to researchers’ investigation of lower observed cancer and diabetes rates in an Ecuadorean cohort. The condition is recessive, so a person must inherit the relevant gene from both parents to develop symptoms. Of 840 known people with the condition worldwide, the BBC says most live in Ecuador’s southern provinces of El Oro and Loja, making the region an unusually concentrated setting for long-term observation.

The observational findings do not establish that Laron syndrome, low IGF-1 or any single biological pathway prevents cancer. María del Cisne Romero’s colon-cancer diagnosis underscores that people with the condition are not immune. There is also an unresolved conflict in the proposed mechanism: Professor Zvi Laron says people treated with IGF-1 during childhood also did not develop cancer in his observations, suggesting IGF-1 alone may not explain the pattern. Researchers are using mouse and pig studies to investigate the full reason, and no preventive treatment has yet resulted.

Professor Laron’s paper, expected later in July 2026, may provide a fuller accounting of known Laron syndrome cases and growth-hormone receptor variants. More important for clinical implications will be evidence from the ongoing animal studies and any subsequent human research that can distinguish association from a treatment-ready mechanism.